Assessment of the Evolution of Cancer Treatment Therapies
Tóm tắt
Cancer therapy has been characterized throughout history by ups and downs, not only due to the ineffectiveness of treatments and side effects, but also by hope and the reality of complete remission and cure in many cases. Within the therapeutic arsenal, alongside surgery in the case of solid tumors, are the antitumor drugs and radiation that have been the treatment of choice in some instances. In recent years, immunotherapy has become an important therapeutic alternative, and is now the first choice in many cases. Nanotechnology has recently arrived on the scene, offering nanostructures as new therapeutic alternatives for controlled drug delivery, for combining imaging and treatment, applying hyperthermia, and providing directed target therapy, among others. These therapies can be applied either alone or in combination with other components (antibodies, peptides, folic acid, etc.). In addition, gene therapy is also offering promising new methods for treatment. Here, we present a review of the evolution of cancer treatments, starting with chemotherapy, surgery, radiation and immunotherapy, and moving on to the most promising cutting-edge therapies (gene therapy and nanomedicine). We offer an historical point of view that covers the arrival of these therapies to clinical practice and the market, and the promises and challenges they present.
Từ khóa
Tài liệu tham khảo
Gilman, 1946, Symposium on advances in pharmacology resulting from war research: Therapeutic applications of chemical warfare agents, Fed. Proc., 5, 285
Goodman, 1946, Nitrogen mustard therapy: Use of methyl-bis (h-chloroethyl) amine hydrochloride and tris (h-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia, and certain allied and miscellaneous disorders, JAMA, 132, 126, 10.1001/jama.1946.02870380008004
Farber, 1948, Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin), N. Engl. J. Med., 238, 787, 10.1056/NEJM194806032382301
Hitchings, 1954, The chemistry and biochemistry of purine analogs, Ann. N. Y. Acad. Sci., 60, 195, 10.1111/j.1749-6632.1954.tb40008.x
Elion, 1954, Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites, J. Biol. Chem., 208, 477, 10.1016/S0021-9258(18)65573-5
Heidelberger, 1957, Fluorinated pyrimidines. A new class of tumor inhibitory compounds, Nature, 179, 663, 10.1038/179663a0
Pearson, 1949, ACTH- and cortisone-induced regression of lymphoid tumors in man: A preliminary report, Cancer, 2, 943, 10.1002/1097-0142(194911)2:6<943::AID-CNCR2820020602>3.0.CO;2-P
Li, 1958, Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists, N. Engl. J. Med., 259, 66, 10.1056/NEJM195807102590204
Johnson, 1963, The vinca alkaloids: A new class of oncolytic agents, Cancer Res., 23, 1390
Brunner, 1965, A methylhydrazine derivative in Hodgkin's disease and other malignant neoplasms. Therapeutic and toxic effects studied in 51 patients, Ann. Intern. Med., 63, 69, 10.7326/0003-4819-63-1-69
DeVita, 1966, Preliminary clinical studies with ibenzmethyzin, Clin. Pharmacol. Ther., 7, 542, 10.1002/cpt196674542
Moxley, 1965, Intensive combination chemotherapy and X-irradiation in the treatment of Hodgkin's disease, Proc. Am. Assoc. Cancer Res., 6, 15
Moxley, 1967, Intensive combination chemotherapy and X-irradiation in Hodgkin's disease, Cancer Res., 27, 1258
Serpick, 1967, Combination chemotherapy in the treatment of advanced Hodgkin's disease, Proc. Am. Assoc. Cancer Res., 8, 13
Serpick, 1970, Combination chemotherapy in the treatment of advanced Hodgkin's disease, Ann. Intern. Med., 73, 881, 10.7326/0003-4819-73-6-881
DeVita, 1975, Advanced diffuse histiocytic lymphoma, a potentially curable disease. Results with combination chemotherapy, Lancet, 1, 248, 10.1016/S0140-6736(75)91142-3
Einhorn, 1979, Combination chemotherapy in disseminated testicular cancer: The Indiana University experience, Semin. Oncol., 6, 87
Einhorn, 1977, Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer, Ann. Int. Med., 87, 293, 10.7326/0003-4819-87-3-293
Einhorn, 1981, Testicular cancer as a model for a curable neoplasm: The Richard and Linda Rosenthal Foundation award lecture, Cancer Res., 41, 3275
Manning, 2002, The protein kinase complement of the human genome, Science, 298, 1912, 10.1126/science.1075762
Krause, 2005, Tyrosine kinases as targets for cancer therapy, N. Engl. J. Med., 353, 172, 10.1056/NEJMra044389
Miles, 1908, A method of performing abdomino-perineal excision for carcinoma of the rectum and of the terminal portion of the pelvic colon, Lancet, 2, 1812, 10.1016/S0140-6736(00)99076-7
Davies, 1914, Recent advances in the surgery of the lung and pleura, Br. J. Surg., 1, 228, 10.1002/bjs.1800010211
Naef, 1993, Hugh Morriston Davies: First dissection lobectomy in 1912, Ann. Thorac. Surg., 56, 988, 10.1016/0003-4975(93)90377-T
Sherwood, 2007, Lung cancer: New surgical approaches, Respirology, 12, 326, 10.1111/j.1440-1843.2007.01083.x
Singletary, 2001, Minimally invasive techniques in breast cancer treatment, Semin. Surg. Oncol., 20, 246, 10.1002/ssu.1040
Genden, 2007, Evolution of the management of laryngeal cancer, Oral. Oncol., 43, 431, 10.1016/j.oraloncology.2006.08.007
Hashizume, 2007, MRI-guided laparoscopic and robotic surgery for malignancies, Int. J. Clin. Oncol., 12, 94, 10.1007/s10147-007-0664-z
Hall, 2006, Intensity-modulated radiation therapy, protons, and the risk of second cancers, Int. J. Radiat. Oncol. Biol. Phys., 65, 1, 10.1016/j.ijrobp.2006.01.027
Murphy, M.J., and Li, T. (2010). Image-Guided and Adaptive Radiation Therapy, Lippincott Williams & Wilkins.
Kohler, 1975, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 256, 495, 10.1038/256495a0
Hozumi, 1976, Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions, Proc. Natl. Acad. Sci. USA, 73, 3628, 10.1073/pnas.73.10.3628
Miller, 1982, Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody, N. Engl. J. Med., 306, 517, 10.1056/NEJM198203043060906
Traggiai, 2004, An efficient method to make monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus, Nat. Med., 10, 871, 10.1038/nm1080
Karpas, 2001, A human myeloma cell line suitable for the generation of human monoclonal antibodies, Proc. Natl. Acad. Sci. USA, 98, 1799, 10.1073/pnas.98.4.1799
Jain, 1987, Transport of molecules across tumor vasculature, Cancer Metastasis Rev., 6, 559, 10.1007/BF00047468
Better, 1988, Escherichia coli secretion of an alive chimeric antibody fragment, Science, 240, 1041, 10.1126/science.3285471
Skerra, 1988, Assembly of a functional immunoglobulinFv fragment in Echerichia coli, Science, 240, 1038, 10.1126/science.3285470
Ayala, 1999, High cytoplasmic expression in Escherichia coli, purification and in vitro refolding of a single chain of Fv antibody against the Hepatitis B surface antigen, J. Biotechnol., 72, 13, 10.1016/S0168-1656(99)00036-X
Valladares, 2002, Production of antigen-specific human monoclonal antibodies from translocus mice: Comparison of mice carrying IgH/Igκ or IgH/IgKIgλLtransloci, Biotechniques, 33, 680, 10.2144/02333dd04
Molina, 2003, The use of transgenic mice for the production of a human monoclonal antibody specific for human CD69 antigen, J. Inmunol. Methods, 282, 147, 10.1016/j.jim.2003.08.007
Valladares, 2004, H24: A human monoclonal antibody obtained from mice carrying human Ig genes, recognizes human myeloid leukaemia and CD5− no Hodgkińs lymphoma, Inmunología, 23, 7
Valladares, 2006, Rearrangement of only one human IGHV gene is sufficient to generate a wide repertoire of antigen specific antibody responses in transgenic mice, Mol. Immunol., 43, 1827, 10.1016/j.molimm.2005.10.015
Caravella, 2010, Design of next-generation protein therapeutics, Curr. Opin. Chem. Biol., 14, 520, 10.1016/j.cbpa.2010.06.175
National Cancer Institute Available online: http://www.cancer.gov/ (accessed on March 2011).
Zhang, 2008, Nanoparticles in medicine: Therapeutic applications and developments, Clin. Pharmacol. Ther., 83, 761, 10.1038/sj.clpt.6100400
Bergin, J. (2011). Nanobiotechnology: Applications and Global Markets., BCC Research. Report Code: NAN050A.
US National Institutes of Health Clinical trials database; search keywords: cancer and nanoparticles; cancer and nano. Available online: http://clinicaltrials.gov/ (accessed on March 2011).
Lu, 2002, Folate-mediated delivery of macromolecular anticancer therapeutic agents, Adv. Drug Deliv. Rev., 54, 675, 10.1016/S0169-409X(02)00042-X
Gullotti, 2009, Extracellularly activated nanocarriers: A new paradigm of tumor targeted drug delivery, Mol. Pharma., 6, 1041, 10.1021/mp900090z
Shi, 2010, Nanotechnology in drug delivery and tissue engineering: From discovery to applications, Nano Lett., 10, 3223, 10.1021/nl102184c
Lanza, 2010, Theragnostics for tumor and plaque angiogenesis with perfluorocarbonnanoemulsions, Angiogenesis, 13, 189, 10.1007/s10456-010-9166-0
Qian, 2008, In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags, Nat. Biotech., 26, 83, 10.1038/nbt1377
Chertok, 2008, Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors, Biomaterials, 29, 487, 10.1016/j.biomaterials.2007.08.050
Sun, 2008, Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles, Nanomedicine, 3, 495, 10.2217/17435889.3.4.495
Weng, 2008, Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo, Nano Lett., 8, 2851, 10.1021/nl801488u
Dhar, 2008, Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles, Proc. Natl. Acad. Sci. USA, 11, 17356, 10.1073/pnas.0809154105
Chatterjee, 2008, Nanoparticles in photodynamic therapy: An emerging paradigm, Adv. Drug Deliv. Rev., 60, 1627, 10.1016/j.addr.2008.08.003
Fayter, 2010, A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin, Health Technol. Assess, 14, 1, 10.3310/hta14370
Huang, 2008, Plasmonic photothermal therapy (PPTT) using gold nanoparticles, Lasers Med. Sci., 23, 217, 10.1007/s10103-007-0470-x
Roy, 2003, Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: A novel drug–carrier system for photodynamic therapy, J. Am. Chem. Soc, 125, 7860, 10.1021/ja0343095
Yan, 2003, The embedding of meta-tetra(hydroxyphenyl)-chlorin into silica nanoparticle platforms for photodynamic therapy and their singlet oxygen production and pH-dependent optical properties, Photochem. Photobiol., 78, 587, 10.1562/0031-8655(2003)078<0587:TEOMIS>2.0.CO;2
Bechet, 2008, Barberi-Heyob, M.Nanoparticles as vehicles for delivery of photodynamic therapy agents, Trends Biotech., 26, 612, 10.1016/j.tibtech.2008.07.007
Griffin, 2010, Mild temperature hyperthermia and radiation therapy: Role of tumor vascular thermotolerance and relevant physiological factors, Int. J. Hyperth., 26, 256, 10.3109/02656730903453546
Hurwitz, 2010, Today's thermal therapy: Not your father's hyperthermia: Challenges and opportunities in application of hyperthermia for the 21st century cancer patient, Am. J. Clin. Oncol., 33, 96, 10.1097/COC.0b013e3181817a75
Moros, 2010, Present and future technology for simultaneous superficial thermoradiotherapy of breast cancer, Int. J. Hyperth., 26, 699, 10.3109/02656736.2010.493915
Issels, 2010, Neoadjuvant chemotherapy alone or with regional hyperthermia for localized high-risk soft-tissue sarcoma: A randomised phase 3 multicentre study, Lancet Oncol., 11, 561, 10.1016/S1470-2045(10)70071-1
Sanvicens, 2008, Multifunctional nanoparticles--properties and prospects for their use in human medicine, Trends Biotechnol., 26, 425, 10.1016/j.tibtech.2008.04.005
Jordan, 2006, The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma, J. Neurooncol., 78, 7, 10.1007/s11060-005-9059-z
Kawai, 2005, Anticancer effect of hyperthermia on prostate cancer mediated by magnetite cationic liposomes and immune-response induction in transplanted syngeneic rats, Prostate, 64, 373, 10.1002/pros.20253
Johannsen, 2007, ; Loening, SA. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: Results of a prospective phase I trial, Int. J. Hyperth., 23, 315, 10.1080/02656730601175479
Rothe, 2007, Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: Results of a feasibility study on patients with glioblastomamultiforme, J. Neurooncol., 81, 53, 10.1007/s11060-006-9195-0
Lehmann, 2008, Nanoparticle thermotherapy and external beam radiation therapy for human prostate cancer cells, Cancer Biother. Radiopharma, 23, 265, 10.1089/cbr.2007.0411
Johannsen, 2010, Magnetic nanoparticle hyperthermia for prostate cancer, Int. J. Hyperth., 26, 790, 10.3109/02656731003745740
Yanase, 1998, Intracellular hyperthermia for cancer using magnetite cationic liposomes: An in vivo study, Jpn. J. Cancer Res., 89, 463, 10.1111/j.1349-7006.1998.tb00586.x
Kikumori, 2009, Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes, Breast Cancer Res. Treat., 113, 435, 10.1007/s10549-008-9948-x
Purushotham, 2009, Thermoresponsive core-shell magnetic nanoparticles for combined modalities of cancer therapy, Nanotechnology, 20, 305101, 10.1088/0957-4484/20/30/305101
Welch, A., and van Gemert, M. (1995). Optical-Thermal Response of Laser-Irradiated Tissue, Plenum Press.
Oldenburg, 1998, Nanoengineering of optical resonances, Chem. Phys. Lett., 288, 243, 10.1016/S0009-2614(98)00277-2
Nanospectra Biosciences Inc. Available online: http://www.nanospectra.com/(accessed on March 2011).
Gobin, 2010, Near-infrared-resonant gold/gold sulfide nanoparticles as a photothermal cancer therapeutic agent, Small, 6, 745, 10.1002/smll.200901557
Lu, 2009, Targeted photothermal ablation of murine melanomas with melanocyte-stimulating hormone analog-conjugated hollow gold nanospheres, Clin. Cancer Res., 15, 876, 10.1158/1078-0432.CCR-08-1480
Park, 2009, Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas, Cancer Res., 69, 3892, 10.1158/0008-5472.CAN-08-4242
Bernardi, 2008, Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: An in vitro evaluation using human cell lines, J. Neurooncol., 86, 165, 10.1007/s11060-007-9467-3
Choi, 2007, A cellular trojan horse for delivery of therapeutic nanoparticles into tumors, Nano Lett., 7, 3759, 10.1021/nl072209h
Pisanic, 2007, Nanotoxicity of iron oxide nanoparticle internalization in growing neurons, Biomaterials, 28, 2572, 10.1016/j.biomaterials.2007.01.043
Wu, 2010, Toxic effects of iron oxide nanoparticles on human umbilical vein endothelial cells, Int. J. Nanomedicine, 5, 385, 10.2147/IJN.S10458
Gajdosikova, 2006, Acute toxicity of magnetic nanoparticles in mice, Neuro. Endocrinol. Lett., 27, 96
Shubayev, 2009, Magnetic nanoparticles for theragnostics, Adv. Drug Deliv. Rev., 61, 467, 10.1016/j.addr.2009.03.007
Elsabahy, 2011, Non-Viral Nucleic Acid Delivery: Key challenges and future directions, Curr. Drug Deliv., 8, 235, 10.2174/156720111795256174
Xu, 2006, Inorganic nanoparticles as carriers for efficient cellulardelivery, Chem. Eng. Sci., 61, 1027, 10.1016/j.ces.2005.06.019
Pikkarainen, 2008, Gene therapy: The first approvedgene-based medicines, molecular mechanisms and clinical indications, Curr. Mol. Pharmacol., 1, 13, 10.2174/1874467210801010013
The Journal of Gene Medicine. http://onlinelibrary.wiley.com/journal/10.1002/(ISSN1521-2254). Available online: http://www.wiley.com/legacy/wileychi/genmed/clinical/ (accessed onMarch 2011).
Brand, K. (2009). Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Taylor and Francis Group LLC. [3rd ed.].
Alemany, 2000, Replicative adenoviruses for cancer therapy, Nat. Biotechnol., 18, 723, 10.1038/77283
Vilaboa, 2006, Regulatable gene expression systems for gene therapy, Curr. Gene Ther., 6, 421, 10.2174/156652306777934829
Peng, 2005, Current status of gendicine in China: Recombinant human Ad-p53 agent for treatment of cancers, Hum. Gene Ther., 16, 1016, 10.1089/hum.2005.16.1016
Yu, 2007, Clinical trials with oncolytic adenovirus in China, Curr. Cancer Drug Targets, 7, 141, 10.2174/156800907780058817
Langford, 2009, A preclinical assessment of the safety and biodistribution of an adenoviral vector containing the herpes simplex virus thymidine kinase gene (Cerepro) after intracerebral administration, J. Gene Med., 11, 468, 10.1002/jgm.1328
Dirven, 2010, Sitimageneceradenovec: A gene-based drug for the treatment of operable high-grade glioma, Future Oncol., 6, 1691, 10.2217/fon.10.134
Nemunaitis, 2009, Biomarkers predict p53 gene therapy efficacy in recurrent, squamous cell carcinoma of the head and neck, Clin. Cancer Res., 15, 7719, 10.1158/1078-0432.CCR-09-1044
Bolhassani, 2011, Improvement of different vaccine delivery systems for cancer therapy, Mol. Cancer, 10, 3, 10.1186/1476-4598-10-3
GenVec, Inc. Available online: http://www.genvec.com(accessed on April 2011).
Weichselbaum, 2009, Translation of the radio- and chemo-inducible TNFerade vector to thetreatment of human cancers, Cancer Gene Ther., 16, 609, 10.1038/cgt.2009.37
Epeius Biotechnologies Corporation® Available online: http://www.epeiusbiotech.com/(accessed on April 2011).
Hall, 2000, Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor, Hum. Gene Ther., 11, 983, 10.1089/10430340050015293
Gordon, 2000, Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct, Cancer Res., 60, 3343
Gordon, 2010, Noteworthy clinical case studies in cancer gene therapy: Tumor-targeted Rexin-G advances as an efficacious anti-cancer agent, Int. J. Oncol., 36, 1341, 10.3892/ijo_00000619
Brown, 2001, Gene delivery with synthetic (non viral) carriers, Int. J. Pharm, 229, 1, 10.1016/S0378-5173(01)00861-4
Nabel, 1993, Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans, Proc. Natl Acad. Sci. USA, 90, 11307, 10.1073/pnas.90.23.11307
Rowe, R.C., Sheskey, P.J., and Owen, S.C. (2006). Handbook of Pharmaceutical Excipients, Pharmaceutical Press.
Bedikian, 2010, A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma, Melanoma Res., 20, 218, 10.1097/CMR.0b013e3283390711
Anwer, 2010, Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer, Gene Ther., 17, 360, 10.1038/gt.2009.159
Li, 2008, Tumor-targeted delivery of siRNA by self-assembled nanoparticles, Mol. Ther., 16, 163, 10.1038/sj.mt.6300323
Yoshizawa, 2008, Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts, Eur. J. Pharm. Biopharm, 70, 718, 10.1016/j.ejpb.2008.06.026
Hattori, 2005, Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase, Cancer Gene Ther., 12, 796, 10.1038/sj.cgt.7700844
Kommareddy, 2007, Antiangiogenic gene therapy with systemically administered sFlt-1 plasmid DNA in engineered gelatin-based nanovectors, Cancer Gene Ther., 14, 488, 10.1038/sj.cgt.7701041
Tan, 2007, Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference, Biomaterials, 28, 1565, 10.1016/j.biomaterials.2006.11.018
Ito, 2001, Heat-inducible TNF-alpha gene therapy combined with hyperthermia using magnetic nanoparticles as a novel tumor-targeted therapy, Cancer Gene Ther., 8, 649, 10.1038/sj.cgt.7700357